A Pair Of Biotechs Bet On The IPO Market
This article was originally published in The Pink Sheet Daily
Executive Summary
Kythera and Intercept completed initial public offerings on the same day, both garnering prices at the high end of their anticipated offering ranges.
You may also be interested in...
Kythera Doubles Down On Double Chins With Bayer Buyback
The biotech buys back rights to its own drug after attaining a more advantageous financial position and successful late-stage results.
Intercept Stock Price Skyrockets On Continuing Stream Of Good Data For OCA Candidates
Early stop due to efficacy of NIH Phase II trial in non-alcoholic steatohepatitis could mean quick pathway to approval for compound in this unmet medical need. A growing liver disease, Intercept believes NASH is an under-recognized opportunity, which could outstrip HCV and cirrhosis as a cause of liver transplantation.
With Twists And Turns, KaloBios Goes Public
It wasn’t pretty, but KaloBios Pharmaceuticals went public and raised $70 million in late January, the first IPO for a US antibody company in more than a decade.